Evidence map›Paper›PMID 39134362›Full record

ArticleLife science alliance2024

Neutrophil-avid nanocarrier uptake by STAT3 dominant-negative hyper-IgE syndrome patient neutrophils.

Kathryn M Rubey, Alexandra Freeman, Alexander R Mukhitov, Andrew J Paris, Susan M Lin, Ryan Rue, Hossein Fazelinia, Lynn A Spruce, Jennifer Roof, Jacob S Brenner and 2 more

Abstract read
In one paragraph

Article in Life science alliance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kathryn M RubeyDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA rubeyk@chop.edu.ORCID 0000-0003-2359-5628
Alexandra FreemanLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Alexander R MukhitovDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Andrew J ParisDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Susan M LinDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ryan RueDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hossein FazeliniaThe Proteomics Core Facility, The Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA, USA.
Lynn A SpruceThe Proteomics Core Facility, The Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA, USA.
Jennifer RoofThe Proteomics Core Facility, The Children's Hospital of Philadelphia, Research Institute, Philadelphia, PA, USA.ORCID 0000-0003-3852-1330
Jacob S BrennerDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jennifer HeimallDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Vera P KrymskayaDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-0584-4486

Funding

Institutional Clinical and Translational Science AwardKL2TR001879 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$13.7M
TRAINING IN PULMONARY IMMUNOLOGYT32HL007586 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MEYER, NUALA JENNINGS · 1985 to 2025
$8.8M
The Molecular and Genetic Pathogensis of LAMU01HL131022 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HENSKE, ELIZABETH P · 2016 to 2024
$5.7M
mTORC1 and WNT in lung mesenchymeR01HL158737 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KRYMSKAYA, VERA P · 2021 to 2024
$2.5M
mTOR signaling in lung homeostasis, aging and diseaseR01HL151467 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KRYMSKAYA, VERA P · 2020 to 2023
$2.0M
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)R01HL141462 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KRYMSKAYA, VERA P, STEPANOVA, VICTORIA · 2019 to 2022
$1.8M
Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous SclerosisR41HL156767 · NHLBI · BIOSPUTNIK LLC · PI KRYMSKAYA, VERA P, PLEIMES, DIRK · 2021 to 2021
$256k
Development of Neutrophil-Avid Nanocarriers as an Antibiotic Delivery SystemF32HL151026 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI RUBEY, KATHRYN · 2020 to 2022
$238k
Pulmonary Endothelial-Mesenchymal Crosstalk in Hyperactive mTOR Lung DiseasesF32HL162425 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LIN, SUSAN M · 2022 to 2022
$25k
NCATS NIH HHS KL2 TR001879NHLBI NIH HHS F32 HL151026NHLBI NIH HHS F32 HL162425NHLBI NIH HHS L40 HL159788NHLBI NIH HHS R01 HL141462NHLBI NIH HHS R01 HL151467NHLBI NIH HHS R01 HL158737NHLBI NIH HHS R41 HL156767NHLBI NIH HHS T32 HL007586NHLBI NIH HHS U01 HL131022
6 · The paper itself

Abstract

Recurrent infections are a hallmark of STAT3 dominant-negative hyper-IgE syndrome (STAT3 HIES), a rare immunodeficiency syndrome previously known as Jobs syndrome, along with elevated IgE levels and impaired neutrophil function. We have been developing nanoparticles with neutrophil trophism that home to the sites of infection via these first-responder leukocytes, named neutrophil-avid nanocarriers (NANs). Here, we demonstrate that human neutrophils can phagocytose nanogels (NGs), a type of NAN, with enhanced uptake after particle serum opsonization, comparing neutrophils from healthy individuals to those with STAT3 HIES, where both groups exhibit NG uptake; however, the patient group showed reduced phagocytosis efficiency with serum-opsonized NANs. Proteomic analysis of NG protein corona revealed complement components, particularly C3, as predominant in both groups. Difference between groups includes STAT3 HIES samples with higher neutrophil protein and lower acute-phase protein expression. The study suggests that despite neutrophil dysfunction in STAT3 HIES, NANs have potential for directed delivery of cargo therapeutics to improve neutrophil infection clearance.

Indexed as

Job SyndromeNanoparticlesNeutrophilsPhagocytosisSTAT3 Transcription FactorAdultComplement C3FemaleHumansImmunoglobulin EMaleProteomicsComplement C3Immunoglobulin ESTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID39134362
PMCPMC11321353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.